Part D Cost Sharing Based On Net Price, Boost For ‘High Discount’ Biosimilars Proposed In Draft Bill

 
• By Cathy Kelly

Senate Finance Committee’s PBM legislation would essentially pass through rebate value at the pharmacy counter for some drugs, block situations where beneficiaries pay more than plans and reward biosimilars that have list prices substantially below their reference products.

Lobbying To Reform PBM Rebate Practices Continues • Source: Shutterstock

Coinsurance obligations for Medicare Part D beneficiaries would be based on the net, post-rebate price of certain drugs for chronic conditions under a legislative discussion draft released by the Senate Finance Committee.

The committee plans to mark up the draft bill, which also includes policies related to pharmacy benefit manager contracts with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet